

Motilal Oswal Financial Services Limited CIN: L67190MH2005PLC153397 Regd. Off.: Motilal Oswal Tower, Rahimtullah Sayani Road, Opp. Parel ST Depot, Prabhadevi, Mumbai – 400025 Board: +91 22 7193 4200 / 4263 Fax: +91 22 5036 2365

September 01, 2023

BSE LimitedNational Stock Exchange of India LimitedP. J. Towers,Exchange Plaza, Plot No. C/1, G Block,Dalal Street, Fort,Bandra-Kurla Complex, Bandra (E),Mumbai - 400001Mumbai - 400051Security code: 532892Symbol: MOTILALOFS

<u>Subject: Acquisition of/ Investment into Equity Shares of Gufic Biosciences Limited</u> ("Gufic")

Dear Sir/Madam,

We are pleased to inform the Exchange that the Finance Committee of Motilal Oswal Financial Services Limited ("MOFSL" or "the Company") at its Meeting held today i.e. September 01, 2023 has approved the proposal to make an investment in Gufic Biosciences Limited ("Gufic"/"the Investee Company") in lines with MOFSL's fund based investment strategy. The said investment will be made by acquiring and/or subscribing to 33,33,000 Equity Shares having face value of Re. 1/- each at Rs. 300/- per Share for a consideration of Rs. 99.99 Crore contributing to 3.32% of the post paid-up share capital of Gufic by way of Preferential issue.

In view of the above and pursuant to the provisions of Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended) read with SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, please find below detailed information:

Sr.	Particulars	Information		
No.				
1.		Name: Gufic Biosciences Limited		
	brief such as size, turnover etc.	("Gufic").		
		Authorised Share Capital: Rs. 85,75,00,000		
		Paid up Share Capital: Rs. 9,69,44,506		

Registration Nos.: INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412; AMFI:ARN-146822; Insurance Corporate Agen: CA0579; Email: shareholders@motilaloswal.com



Motilal Oswal Financial Services Limited CIN: L67190MH2005PLC153397 Regd. Off.: Motilal Oswal Tower, Rahimtullah Sayani Road, Opp. Parel ST Depot, Prabhadevi, Mumbai – 400025 Board: +91 22 7193 4200 / 4263 Fax: +91 22 5036 2365

		Size/Turnover: Rs. 69,062.08 Lakhs (For the year ended March 31, 2023)	
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Investment in Gufic does not constitute a related party transaction. Save and except what is mentioned above, MOFSL's promoter/ promoter group are not interested in the aforementioned transaction.	
3.	Industry to which the entity being acquired belongs	Gufic is engaged in the Research & Development, manufacturing, marketing, distribution and sale of pharmaceutical and allied products	
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This acquisition is a long term financial investment of the Company in line with its Fund Based Investments strategy.	
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Governmental or regulatory approval is not required.	
6.	Indicative time period for completion of the acquisition	Within a period of 2 Months from this intimation, subject to approval of shareholders and other statutory /regulatory approvals of the Investee Company.	
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration.	
8.	Cost of acquisition or the price at which the shares are Acquired	33,33,000 Equity Shares having face value of Re. 1/- each at Rs. 300/- per Share for a consideration of Rs. 99.99 Crore.	

Registration Nos.: INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412; AMFI:ARN-146822; Insurance Corporate Agen: CA0579; Email: shareholders@motilaloswal.com

MOTILAL OSWAL

Motilal Oswal Financial Services Limited CIN: L67190MH2005PLC153397 Regd. Off.: Motilal Oswal Tower, Rahimtullah Sayani Road, Opp. Parel ST Depot, Prabhadevi, Mumbai – 400025 Board: +91 22 7193 4200 / 4263 Fax: +91 22 5036 2365

9.	Percentage of shareholding / control acquired and / or number of shares acquired	Post investment, MOFSL will hold 33,33,000 fully paid up Equity Shares having face value of Re. 1/- each which consist 3.32% of total paid up capital of the Gufic.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Gufic was incorporated on July 23, 1984 in Maharashtra, India. Gufic is engaged in the R&D, manufacturing, marketing, distribution and sale of pharmaceutical and allied products. Gufic is known and respected for innovative and high quality pharmaceutical and herbal products along with a wide range of Active Pharmaceutical Ingredients (APIs). Gufic is one of the fastest growing company among the top 100 pharma companies in India and is also one of the largest manufacturers of Lyophilized injections in India having a fully automated lyophilization plant. The lyophilized products are available in Therapeutic areas like Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and Proton-Pump Inhibitor (PPI). Gufic is now augmenting its global focus by deepening the presence in the priority markets of India, Germany, Switzerland, South Africa, Russia, Canada, Europe and other key countries within the emerging market territories. Gufic aims at providing lifesaving drugs to people at affordable prices with no compromise in its quality. Gufic is a WHO-GMP, EU GMP, ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia

Registration Nos.: INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412; AMFI:ARN-146822; Insurance Corporate Agen: CA0579; Email: shareholders@motilaloswal.com



Motilal Oswal Financial Services Limited CIN: L67190MH2005PLC153397 Regd. Off.: Motilal Oswal Tower, Rahimtullah Sayani Road, Opp. Parel ST Depot, Prabhadevi, Mumbai – 400025 Board: +91 22 7193 4200 / 4263 Fax: +91 22 5036 2365

NDA approved c	History of Gufic's Turnover:	
History of Gufic's T Financial Year		
2022-23	69,062.08/-	
2021-22	77,915.56 / -	
2020-21	48,769.87/-	

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Motilal Oswal Financial Services Limited

Kailash Purohit Company Secretary & Compliance Officer